Carvedilol for Cardioprotection in Breast Cancer
(CCTGuide Pilot Trial)
What You Need to Know Before You Apply
What is the purpose of this trial?
This trial is testing if carvedilol, a heart-protecting medication, is safe and effective for breast cancer patients who are at high risk of heart problems from their cancer treatments. Carvedilol helps by reducing the workload and stress on the heart.
Who Is on the Research Team?
Bonnie Ky, MD, MSCE
Principal Investigator
Perelman School of Medicine at the University of Pennsylvania
Are You a Good Fit for This Trial?
This trial is for women over 18 with Stage I-III breast cancer who are about to receive anthracyclines and/or trastuzumab. They must have a measurable heart function score and not be pregnant or breastfeeding. Exclusions include asthma, current beta blocker use, low blood pressure, certain heart conditions, severe liver issues, and use of specific medications.Inclusion Criteria
Exclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants receive carvedilol in a risk-guided strategy alongside doxorubicin and/or trastuzumab
Follow-up
Participants are monitored for safety and effectiveness after treatment
What Are the Treatments Tested in This Trial?
Interventions
- Carvedilol
Find a Clinic Near You
Who Is Running the Clinical Trial?
Abramson Cancer Center at Penn Medicine
Lead Sponsor
Abramson Cancer Center of the University of Pennsylvania
Lead Sponsor